ATE480553T1 - Replikin-peptide und anwendungen - Google Patents

Replikin-peptide und anwendungen

Info

Publication number
ATE480553T1
ATE480553T1 AT04785929T AT04785929T ATE480553T1 AT E480553 T1 ATE480553 T1 AT E480553T1 AT 04785929 T AT04785929 T AT 04785929T AT 04785929 T AT04785929 T AT 04785929T AT E480553 T1 ATE480553 T1 AT E480553T1
Authority
AT
Austria
Prior art keywords
peptides
replicin
applications
diagnosing
preventing
Prior art date
Application number
AT04785929T
Other languages
English (en)
Inventor
Samuel Bogoch
Elenore Bogoch
Original Assignee
Samuel Bogoch
Bogoch Elenore S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel Bogoch, Bogoch Elenore S filed Critical Samuel Bogoch
Application granted granted Critical
Publication of ATE480553T1 publication Critical patent/ATE480553T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04785929T 2003-06-06 2004-06-07 Replikin-peptide und anwendungen ATE480553T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47618603P 2003-06-06 2003-06-06
US50495803P 2003-09-23 2003-09-23
US53168603P 2003-12-23 2003-12-23
US10/860,050 US7442761B2 (en) 2003-06-06 2004-06-04 Replikin peptides and uses thereof
PCT/US2004/017936 WO2005010032A2 (en) 2003-06-06 2004-06-07 Replikin peptides and uses thereof

Publications (1)

Publication Number Publication Date
ATE480553T1 true ATE480553T1 (de) 2010-09-15

Family

ID=34109088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04785929T ATE480553T1 (de) 2003-06-06 2004-06-07 Replikin-peptide und anwendungen

Country Status (11)

Country Link
US (2) US7442761B2 (de)
EP (3) EP2338901A1 (de)
JP (1) JP2007526222A (de)
AT (1) ATE480553T1 (de)
AU (2) AU2004259640B2 (de)
CA (1) CA2528440A1 (de)
DE (1) DE602004029034D1 (de)
IL (3) IL172396A (de)
NZ (1) NZ544277A (de)
SG (1) SG182000A1 (de)
WO (1) WO2005010032A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7894999B2 (en) 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
KR100906102B1 (ko) 2001-03-27 2009-07-07 사무엘 보고치 레플리킨 펩타이드 및 그의 이용
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US8494781B2 (en) 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
CA2544848C (en) 2003-11-04 2015-12-29 The Administrators Of The Tulane Educational Fund Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins
US9254315B2 (en) * 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
NZ560415A (en) * 2005-02-16 2010-05-28 Samuel Bogoch Systems and method for identifying replikin scaffolds and uses of said replikin scaffolds
US8299214B2 (en) * 2006-03-13 2012-10-30 Keio University Influenza infection-inhibiting peptide, influenza virus infection inhibitor, liposome, and influenza preventive/therapeutic agent
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US8222204B2 (en) * 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
US20080260764A1 (en) * 2006-05-30 2008-10-23 Samuel Bogoch Replikin peptides and uses thereof
US8050871B2 (en) 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
CA2676028A1 (en) * 2007-01-18 2008-11-27 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
KR20100006574A (ko) * 2007-05-30 2010-01-19 사무엘 보고치 수산 양식되는 무척추동물의 병원체 감염에 대항하는 합성 레플리킨 펩티드
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
WO2013013075A2 (en) 2011-07-20 2013-01-24 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
SG11201405447QA (en) 2012-03-09 2014-10-30 Samuel Bogoch Therapies, vaccines, and predictive methods for infectious salmon anemia virus
ES2710321A1 (es) * 2017-10-20 2019-04-24 Consejo Superior Investigacion Adn polimerasas independientes de cebador y su uso para la sintesis de adn
CN111999508A (zh) * 2020-05-15 2020-11-27 上海交通大学 一种诊断标志物及其在covid-19诊断及冠状病毒既往感染检测中的应用
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132769A (en) * 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
IE56509B1 (en) 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
EP0221748A3 (de) 1985-11-01 1988-10-12 Samuel Dr. Bogoch Verfahren zur Herstellung von menschlichen Antikörpern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5231167A (en) 1989-09-08 1993-07-27 The Regents Of The University Of California Immunoglobulin-binding polypeptides
GB9202219D0 (en) 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
US20050271676A1 (en) 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6242578B1 (en) 1994-02-17 2001-06-05 Samuel Bogoch Aglyco products and methods of use
WO1996032106A1 (en) 1995-04-11 1996-10-17 Samuel Bogoch Aglyco products
US6023659A (en) 1996-10-10 2000-02-08 Incyte Pharmaceuticals, Inc. Database system employing protein function hierarchies for viewing biomolecular sequence data
CA2272845C (en) * 1996-11-26 2010-01-12 Bio Merieux Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
US6070126A (en) 1997-06-13 2000-05-30 William J. Kokolus Immunobiologically-active linear peptides and method of identification
JPH11232291A (ja) 1998-02-16 1999-08-27 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質立体構造データベース検索方法
IT1300059B1 (it) 1998-04-24 2000-04-05 Ist Naz Ric Sul Cancro Peptidi ad attivita' chemiotattica e anti-hiv
US7176275B2 (en) 1998-09-04 2007-02-13 Samuel Bogoch Anthrax and small pox replikins and methods of use
US6175830B1 (en) 1999-05-20 2001-01-16 Evresearch, Ltd. Information management, retrieval and display system and associated method
WO2001004135A2 (en) 1999-07-13 2001-01-18 The Regents Of The University Of Michigan Crosslinked dna condensate compositions and gene delivery methods
US6470277B1 (en) 1999-07-30 2002-10-22 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7452963B2 (en) 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
NZ528819A (en) 2001-03-27 2008-05-30 Samuel Bogoch Identification and use of replikin peptides in influenza viruses
US7420028B2 (en) 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
CA2453136A1 (en) 2001-07-09 2003-01-23 Samuel Bogoch Replikin peptides and uses thereof
US7267942B2 (en) * 2003-03-24 2007-09-11 The University Of Hong Kong Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
US8050871B2 (en) * 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
WO2012075468A1 (en) 2010-12-02 2012-06-07 Mark Olsson Magnetically sensed user interface apparatus and devices

Also Published As

Publication number Publication date
EP2292643A1 (de) 2011-03-09
NZ544277A (en) 2009-02-28
SG182000A1 (en) 2012-07-30
AU2004259640A1 (en) 2005-02-03
DE602004029034D1 (de) 2010-10-21
EP1636254A2 (de) 2006-03-22
US7442761B2 (en) 2008-10-28
AU2010200602A1 (en) 2010-03-11
IL199527A (en) 2013-02-28
IL172396A (en) 2013-01-31
US20090053257A1 (en) 2009-02-26
JP2007526222A (ja) 2007-09-13
AU2004259640B2 (en) 2010-04-01
US20050202415A1 (en) 2005-09-15
EP1636254B1 (de) 2010-09-08
WO2005010032A3 (en) 2005-06-09
WO2005010032A2 (en) 2005-02-03
AU2010200602B2 (en) 2012-12-20
IL204266A (en) 2012-12-31
EP2292643B1 (de) 2015-02-18
IL172396A0 (en) 2006-04-10
EP2338901A1 (de) 2011-06-29
CA2528440A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
DE602004029034D1 (de) Replikin-peptide und anwendungen
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
CY1110721T1 (el) Χρηση glp-2 σε συνδυασμο με αλλο θεραπευτικο παραγοντα σε οστικες παθησεις
DE602004023503D1 (de) Medizinisches behandlungswerkzeug und dieses entha
CY2013004I1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
DOP2002000429A (es) Imidazotriazinas
DE60106151D1 (de) Additionshärtbare Silikonelastomermischungen, ihre Herstellung und Verwendung
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
DE602006002982D1 (de) Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit
IS2482B (is) Arómatísk súlfón og læknisfræðileg notkun þeirra
DK1404304T3 (da) Tablet omfattende cetirizin og pseudoephedrin
UY28344A1 (es) Nuevos compuestos
DE60220833D1 (de) Desinfektionsmittel für medizinische geräte und oberflächenanwendungen
NO20051521L (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
ATE524186T1 (de) Pharmazeutische kombinationen bestehend aus meloxicam, tramadol und paracetamol
ATE411279T1 (de) Arylsulfonamidobenzylverbindungen
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
NL1026326A1 (nl) Patient-ligtafel.
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
PT4255563T (pt) 5¿-o-fenilacetiluridina e uso terapêutico
DE602005007858D1 (de) Medizinische seife
ATE554109T1 (de) Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür
EA200501259A1 (ru) Комбинированное применение фибрата и орлистата для лечения ожирения
ATE538133T1 (de) Replikin-peptide und ihre verwendungszwecke

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties